INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION MASTER MANUFACTURING AND SUPPLY AGREEMENTMaster Manufacturing and Supply Agreement • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This MASTER MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the 25th day of April, 2014 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL PRODUCT ADDENDUM For DOXOPHOSOasmia Pharmaceutical AB • August 14th, 2015 • Pharmaceutical preparations
THIS COMMERCIAL PRODUCT ADDENDUM is an addendum to that certain Master Manufacturing and Supply Agreement of the 25th of April, 2014 by and between BAXTER ONCOLOGY GMBH (“Baxter”), a German company having a place of business at Kantstrasse 2, 33790 Halle / Westphalia, Germany, and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (the “Commercial Supply Agreement”) and shall commence on the 20th day of May, 2014 (“Commercial Product Addendum Effective Date”) and expire at the end of 19th day of May 2019 (the “Commercial Product Addendum Term”).
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This Commercial MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the 16th day of February, 2011 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
